The harsh realities of life can sometimes become a daunting realisation. But today, we can leverage on decades of extensive study and research, particularly in the area of cancer treatment. Premised on the discipline of cell programming technology, AscendNex opens an avenue of positivity in availing ongoing discoveries in cancer research through CAR-T therapy.
Specifically effective with Hematological cancer, Chimeric Antigen Receptor (CAR-T) cells, are the result of introducing a chimeric antigen receptor (CAR) into a type of white blood cell called T cells. Individually expanded in culture from a patient’s blood, it acts as an agent against cancer cells.